Funding agencies: This study was funded by the Italian Ministry of Health RF07, RF08, and RC 08-09/A.
Article first published online: 9 JUN 2011
Copyright © 2011 Movement Disorder Society
Volume 26, Issue 10, pages 1825–1834, 15 August 2011
How to Cite
Assogna, F., Cravello, L., Caltagirone, C. and Spalletta, G. (2011), Anhedonia in Parkinson's disease: A systematic review of the literature. Mov. Disord., 26: 1825–1834. doi: 10.1002/mds.23815
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 26 AUG 2011
- Article first published online: 9 JUN 2011
- Manuscript Accepted: 9 MAY 2011
- Manuscript Revised: 3 MAY 2011
- Manuscript Received: 18 NOV 2010
- Parkinson's disease;
- motor symptoms;
- nonmotor symptoms;
- cognitive deficits;
Anhedonia, defined as lowered ability to experience physical or social pleasure, is a key symptom of several psychiatric illnesses. In this systematic review, we aimed to evaluate the role of anhedonia in Parkinson's Disease and its relationships with other clinical characteristics, dopamine dysfunction, and antiparkinsonian therapy. The database was selected using PubMed Services. Relevant journals were hand-searched, and the bibliographies of all the important articles were scrutinized to find additional publications. Fifteen studies assessed the topic of anhedonia in Parkinson's disease from 1984 to 2009 and mainly described it as a core symptom of depression in patients with Parkinson's disease. Some studies investigated the relationship between anhedonia and neuropsychological symptoms and found correlations with frontal lobe functions. Reports on the relationship between anhedonia and illness severity or motor symptoms are rather inconclusive. No definitive conclusions can be drawn because few studies have been published on this topic. Nevertheless, some evidence suggests that in Parkinson's disease anhedonia is a secondary phenomenon linked to depression, apathy severity, and frontal lobe dysregulation and that it could respond to antiparkinsonian treatment. Future studies of larger samples of patients are strongly required to definitively clarify the relationship between anhedonia and other clinical features, such as depression, anxiety, apathy, cognition, and motor status. Furthermore, more reliable tools and validated diagnostic criteria are necessary to assess anhedonia in patients with Parkinson's disease. © 2011 Movement Disorder Society